.png){kind=small}
.png){kind=small}
.png){kind=small}
The Industry Reality
Regulated innovation carries unique pressure:
-
High compliance requirements
-
Expensive packaging and processing systems
-
Precision and validation complexity
-
Extended timelines before revenue
Building infrastructure before demand is proven increases financial and operational exposure.
The LaunchSpan™ Approach
We enable:
-
Commercial-scale validation under controlled conditions
-
Packaging and throughput testing
-
Margin confirmation before infrastructure build
-
Accelerated time-to-market
-
Reduced financial exposure
This creates clarity before capital is deployed.
Built For
-
Clinical nutrition companies
-
PE-backed healthcare platforms
-
Supplement brands scaling nationally
-
Pharma innovation divisions
Optionality Built In
Once data supports the case, you may:
-
Transition to owned infrastructure
-
Lease or acquire equipment
-
Maintain flexible production
-
Exit without sunk capital
The Economic Value of 1 Year Sooner
Economic Value
Speed to market is not just a strategic advantage.
It is a measurable financial return accelerator.
Let’s model a conservative scenario:
-
$3M upfront CapEx (Traditional path)
-
$25M revenue at maturity
-
20% EBITDA margin
-
$5M annual EBITDA
-
12% discount rate
-
5-year horizon
We’ll compare:
• Traditional build (1-year delay + $3M CapEx)
• LaunchSpan™ (no upfront CapEx + revenue starts Year 1)
Financial Scenario Comparison
Traditional Model
$3M upfront investment
Revenue begins in Year 2.
Year Cash Flow Present Value @12%
0 -$3.0M -$3.0M
1 $0 $0
2 $5.0M $3.99M
3 $5.0M $3.56M
4 $5.0M $3.18M
5 $5.0M $2.84M
Total PV ≈ $10.6M
LaunchSpan™
No upfront CapEx
Revenue begins in Year 1.
Year Cash Flow Present Value @12%
0 $0 $0
1 $5.0M $4.46M
2 $5.0M $3.99M
3 $5.0M $3.56M
4 $5.0M $3.18M
5 $5.0M $2.84M
Total PV ≈ $18.0M
The Financial Impact
Incremental Value from LaunchSpan™:
≈ +$7.4M in Present Value
That increase comes from:
-
Eliminating $3M upfront capital
-
Accelerating revenue by 12 months
-
Improving cash flow timing
-
Increasing reinvestment velocity
The Financial Advantage of LaunchSpan™
Accelerating commercialization by 12 months can dramatically improve financial performance and capital efficiency.
IRR Comparison
Traditional
-
-$3M Year 0
-
$5M annually starting Year 2
IRR ≈ 65%
LaunchSpan™
-
No upfront investment
-
$5M annually starting Year 1
IRR effectively infinite on invested capital
(or materially higher if modeled with working capital only)
Even if you assume LaunchSpan™ includes:
-
$1M variable commercialization cost
IRR still significantly outperforms the traditional build.
Executive Takeaway
1 Year Sooner + No $3M CapEx
= ~70% greater economic value over 5 years
= Faster reinvestment
= Lower capital exposure
= Higher portfolio velocity
This is before factoring:
-
Retail shelf advantage
-
Competitive displacement
-
Reduced financing cost
-
Ability to pursue multiple simultaneous projects
Speed is not a marketing advantage.
It is a capital multiplier.